title: Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer.
abstract: OBJECTIVE
  To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment.
  
  
  METHODS
  A total of 136 patients with advanced CC (FIGO stage: IB2-IIA [12]; IIB [34]; IIIB [71]; IVA [19]; including both epidermoid [86] and adenocarcinoma [14]) were analyzed to determine c-erb-B2 levels by immunohistochemistry (c-erb-B2 antibody; Dako, Glostrup, Denmark). Only c-erb-B2+++ biopsies were considered positive. All patients received pelvic radiotherapy, brachytherapy, and concurrent chemotherapy with 2 different regimens: 48 patients were treated with tegafur (800 mg/d orally) and 88 with tegafur (same doses) plus 5 cycles of weekly cisplatin 40 mg/m/wk intravenously.
  
  
  RESULTS
  A total of 32 (23.5%) biopsies were considered c-erb-B2-positive. Three-year and 5-year DFS were 61% and 58% for c-erb-B2-negative patients and 36% and 36% for c-erB2-positive patients, respectively (P = 0.02). Patients were stratified in 4 groups according to their c-erb-B2 status and whether they received cisplatin. The group of patients with c-erb-B2 overexpression that did not receive platinum treatment had a higher rate of pelvic relapse (P < 0.0001), associated with a decreased DFS (P = 0.0014).
  
  
  CONCLUSIONS
  c-erb-B2 overexpression may imply a poor prognosis for patients with advanced CC. Treatment with cisplatin-based radiochemotherapy improved outcome in these patients.
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Universitario Doce de Octubre, Avenida de Córdoba Km 5.4, 28041 Madrid, Spain. asmoncomed@yahoo.es
authors.forename: José
authors.initials: J
authors.lastname: Pérez-Regadera
authors.forename: Alfonso
authors.initials: A
authors.lastname: Sánchez-Muñoz
authors.forename: Javier
authors.initials: J
authors.lastname: De-la-Cruz
authors.forename: Claudio
authors.initials: C
authors.lastname: Ballestín
authors.forename: David
authors.initials: D
authors.lastname: Lora
authors.forename: Rosa
authors.initials: R
authors.lastname: García-Martín
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Alonso-Carrión
authors.forename: Cesar
authors.initials: C
authors.lastname: Mendiola
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lanzós
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*
chemical_list: D002945:Cisplatin; D018719:Erb-b2 Receptor Tyrosine Kinases; D005641:Tegafur